Effects of fluorescent light-guided transurethral resection on non-muscle-invasive bladder cancer: a systematic review and meta-analysis


Jia Wang, Department of Urology, West China Hospital, Sichuan University, GuoXueXiang 37, Chengdu 610041, China. e-mail: cdhx510@126.com


Study Type – Diagnostic (systematic review)

Level of Evidence 1a

What's known on the subject? and What does the study add?

It was well known that FL-guided TURBT could reduce the residual rate of NMIBC, but our systematic review suggested that it was not superior to conventional WL-guided TURBT in diagnostic accuracy and it had no significant effect on short-term RFS and PFS.


  • • To assess the diagnostic accuracy and therapeutic outcomes of fluorescent light (FL)-guided transurethral resection (TUR) in non-muscle-invasive bladder cancer (NMIBC).


  • • A systematic search of PUBMED, EMBASE and Cochrane Library was performed to identify randomized controlled trials comparing the outcomes of FL- and white-light (WL)-guided TUR of bladder tumours (TURBT).
  • • Outcomes included tumour detection rate, false-positive diagnosis rate, carcinoma in situ (CIS) detection rate, residual tumour rate, recurrence-free survival (RFS) and progression-free survival (PFS).
  • • RevMan 5.1 software was used for the meta-analysis.


  • • Data from 14 studies, involving 4078 patients with suspected or proven NMIBC, were pooled and included in the meta-analysis.
  • • There was no significant difference in tumour detection rate (relative risk [RR] 0.99; 95% confidence interval [CI] 0.96–1.03; P= 0.64) and CIS detection rate (RR 0.82; 95% CI 0.67–1.02; P= 0.07) between the FL and the WL groups.
  • • The false-positive diagnosis rate of the FL group was higher than that of the WL group (RR 0.69; 95% CI 0.49–0.97; P= 0.03).
  • • The tumour residual rate was higher in the WL group than in the FL group (RR 2.77; 95% CI 1.47–5.02; P= 0.002).
  • • No significant differences were found between groups at 3-month follow-up (RR 1.15; 95% CI 0.79–1.66; P= 0.46) or 12-month follow-up (RR 0.86; 95% CI 0.70–1.06; P= 0.16) or in terms of either RFS or PFS at 12-month (RR 0.99; 95% CI 0.94–1.04; P= 0.57) and 24-month follow-up (RR 1.02; 95% CI 0.98–1.06; P= 0.35).


  • • FL-guided TURBT was not superior to conventional WL in diagnostic accuracy. Although FL-guided TURBT had an advantage in reducing the residual tumour rate, it had no significant effect on short-term RFS and PFS.